Market closedNon-fractional
Agios/AGIO
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About Agios
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
Ticker
AGIO
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Cambridge, United States
Employees
385
Website
www.agios.com
Agios Metrics
BasicAdvanced
$2.4B
Market cap
-
P/E ratio
-$6.30
EPS
0.86
Beta
-
Dividend rate
Price and volume
Market cap
$2.4B
Beta
0.86
Financial strength
Current ratio
12.838
Quick ratio
11.635
Long term debt to equity
7.116
Total debt to equity
9.187
Management effectiveness
Return on assets (TTM)
-24.55%
Return on equity (TTM)
-39.61%
Valuation
Price to revenue (TTM)
79.99
Price to book
3.2
Price to tangible book (TTM)
3.2
Price to free cash flow (TTM)
-7.37
Growth
Revenue change (TTM)
54.61%
Earnings per share change (TTM)
58.93%
3-year earnings per share growth
-34.97%
What the Analysts think about Agios
Analyst Ratings
Majority rating from 7 analysts.
Agios Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$8.1M
14.08%
Net income
-$82M
-15.02%
Profit margin
-1,006.17%
-25.51%
Agios Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.51
-$1.64
-$1.72
-$1.45
-
Expected
-$1.56
-$1.70
-$1.65
-$1.65
-$1.60
Surprise
-3.27%
-3.67%
4.38%
-12.06%
-
Agios News
AllArticlesVideos
Agios Pharmaceuticals' blood disorder drug succeeds in late-stage study
Reuters·1 month ago
Agios Announces Phase 3 ENERGIZE-T Study of Mitapivat Met Primary Endpoint and All Key Secondary Endpoints in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia
GlobeNewsWire·1 month ago
Agios to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Agios stock?
Agios (AGIO) has a market cap of $2.4B as of July 04, 2024.
What is the P/E ratio for Agios stock?
The price to earnings (P/E) ratio for Agios (AGIO) stock is 0 as of July 04, 2024.
Does Agios stock pay dividends?
No, Agios (AGIO) stock does not pay dividends to its shareholders as of July 04, 2024.
When is the next Agios dividend payment date?
Agios (AGIO) stock does not pay dividends to its shareholders.
What is the beta indicator for Agios?
Agios (AGIO) has a beta rating of 0.86. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Agios stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.